SITE006-0215

SITE006 (GBR) › SITE006-0215

SITE006-0215

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-05-09

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-02 (study day 78); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 67); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-15 (study day 60); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 33); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 32); relationship: RELATED

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 17); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.